MYC status determination in aggressive B-cell lymphoma: The impact of FISH probe selection

Histopathology

Volumn 63, Issue 3, 2013, Pages 418-424

  Muñoz Mármol, Ana M ^a   Sanz, Carolina ^a,b   Tapia, Gustavo ^a,c   Marginet, Ruth ^a   Ariza, Aurelio ^a,c   Mate, José L ^a,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b H de Badalona Germans Trias I Pujol   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Break apart; Burkitt lymphoma; Diffuse large B cell lymphomas; Dual fusion; Fluorescence in situ hybridization; MYC; Translocation

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER PROGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MOLECULAR PROBE; PRIORITY JOURNAL;

BREAK-APART; BURKITT LYMPHOMA; DIFFUSE LARGE B-CELL LYMPHOMAS; DUAL-FUSION; FLUORESCENCE IN-SITU HYBRIDIZATION; MYC; TRANSLOCATION;

ADULT; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENES, IMMUNOGLOBULIN LIGHT CHAIN; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NUCLEIC ACID PROBES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882683842     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12178     Document Type: Article

References (30)

1. Swerdlow SH, Campo E, Harris NL et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008.
2. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J. Clin. Oncol. 2011; 29; 1835-1843.
3. Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol. Dis. 2010; 45; 317-323.
4. Barrans S, Crouch S, Smith A et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. 2010; 28; 3360-3365.
5. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114; 3533-3537.
6. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3452-3459.
7. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3460-3467.
8. Cuccuini W, Briere J, Mounier N et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119; 4619-4624.
9. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. 2000; 18; 3707-3721.
10. Molyneux EM, Rochford R, Griffin B et al. Burkitt's lymphoma. Lancet 2012; 379; 1234-1244.
11. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006; 354; 2419-2430.
12. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia 2009; 23; 225-234.
13. Joos S, Falk MH, Lichter P et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum. Mol. Genet. 1992; 1; 625-632.
14. Joos S, Haluska FG, Falk MH et al. Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc. Cancer Res. 1992; 52; 6547-6552.
15. Busch K, Keller T, Fuchs U et al. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14)translocations in sporadic Burkitt-lymphoma. Leukemia 2007; 21; 1739-1751.
16. Einerson RR, Law ME, Blair HE et al. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia 2006; 20; 1790-1799.
17. Bertrand P, Bastard C, Maingonnat C et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 2007; 21; 515-523.
18. Tapia G, Lopez R, Muñoz-Mármol AM et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 2011; 59; 672-678.
19. Kluk MJ, Chapuy B, Sinha P et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 2012; 7; e33813.
20. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2012; 36; 612-619.
21. Fabris S, Storlazzi CT, Baldini L et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosom. Cancer 2003; 37; 261-269.
22. van Rijk A, Mason D, Jones M et al. Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach. J. Hematop. 2008; 1; 119-126.
23. Haralambieva E, Schuuring E, Rosati S et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosom. Cancer 2004; 40; 10-18.
24. Nagel I, Akasaka T, Klapper W et al. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica 2009; 94; 1020-1023.
25. May PC, Foot N, Dunn R, Geoghegan H, Neat MJ. Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. Cancer Genet. Cytogenet. 2010; 198; 71-75.
26. Xicoy B, Ribera JM, Mate JL et al. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. Leuk. Lymphoma 2010; 51; 2063-2069.
27. Ventura RA, Martin-Subero JI, Jones M et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J. Mol. Diagn. 2006; 8; 141-151.
28. Foot NJ, Dunn RG, Geoghegan H, Wilkins BS, Neat MJ. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience. J. Clin. Pathol. 2011; 64; 802-808.
29. Geiersbach K, Rector LS, Sederberg M et al. Unknown partner for USP6 and unusual SS18 rearrangement detected by fluorescence in situ hybridization in a solid aneurysmal bone cyst. Cancer Genet. 2011; 204; 195-202.
30. Mitelman F, Johansson B, Mertens F eds. Mitelman database of chromosome aberrations and gene fusions in cancer. 2012. http://cgap.nci.nih.gov/Chromosomes/Mitelman.